PER 2.22% 9.2¢ percheron therapeutics limited

Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-351

  1. 13,031 Posts.
    lightbulb Created with Sketch. 1344
    https://www.grandviewresearch.com/press-release/global-duchenne-muscular-dystrophy-dmd-drugs-market


    Mutation-specific therapies, such as Translarna, are anticipated to face limited adoption due to premium pricing.
    Associated adverse effects of steroid therapy make them a less favored treatment option

    Mutation -suppressive therapeutics and steroids are projected to witness healthy growth due to increasing adoption of Translarna and EmflazaTranslarna received conditional approval in Europe in 2014 for the treatment of nonsense mutation DMD patients who are in ambulatory state and are 5 years or older. Exondys51 and Emflaza have not been approved for DMD treatment in Europe

    I remember CG talking about steroids being nasty
    and Clinicians don’t like using them
    Heres a chance for ATL1102 to shine $$



    Where is everyone ? Very exciting next 8 weeks

    $5 in time
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
9.2¢
Change
0.002(2.22%)
Mkt cap ! $82.94M
Open High Low Value Volume
8.9¢ 9.2¢ 8.8¢ $69.71K 769.3K

Buyers (Bids)

No. Vol. Price($)
2 35742 9.0¢
 

Sellers (Offers)

Price($) Vol. No.
9.2¢ 84100 2
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
9.2¢
  Change
0.002 ( 3.37 %)
Open High Low Volume
8.9¢ 9.2¢ 8.8¢ 138646
Last updated 15.59pm 14/06/2024 ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.